Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: a survey from the Home Monitoring Expert Alliance (HMEA) project
ConclusionsThis survey showed that RM service was usually set up with a primary nursing model including on average 2 responsible physicians and 1 nurse and mainly offered to ICD/CRT patients. Technical, AF and ventricular arrhythmia alerts triggered prompt reactions, while heart failure related indexes were generally less applied.This article is protected by copyright. All rights reserved.
Publication date: Available online 12 December 2019Source: Canadian Journal of CardiologyAuthor(s): Christopher C. Cheung, Thomas M. Roston, Jason G. Andrade, Matthew T. Bennett, Margot K. DavisAbstractCardiac amyloidosis occurs secondary to the deposition of insoluble protein fibrils in cardiac tissue leading to progressive myocardial dysfunction, clinical heart failure, and arrhythmia. In recent years, increasing awareness and improved screening have resulted in an increased prevalence of cardiac amyloidosis, with contemporary estimates reporting a prevalence of 18 to 55 cases per 100,000 person-years, and accounting for...
ConclusionsNMES is feasible in patients with AHF from immediately after admission.
Conclusion:Cardiac toxicity is not rare in elderly patients with lymphoma, and a comprehensive management strategy is needed.DisclosuresSong: Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Zhu: Beijing Cancer Hospital: Employment.
ConclusionIn this retrospective study, IB-therapy was associated with a substantial increase in the incidence and severity of HTN. Further research into the mechanisms, early detection strategies, optimal management, and clinical impacts of this complication are needed.DisclosuresNo relevant conflicts of interest to declare.
AbstractBackgroundHeart failure is heterogeneous in aetiology, pathophysiology, and presentation. Despite this diversity, clinical trials of patients hospitalized for HF deal with this problem as a single entity, which may be one reason for repeated failures.MethodsThe first EuroHeart Failure Survey screened consecutive deaths and discharges of patients with suspected heart failure during 2000 –2001. Patients were sorted into seven mutually exclusive hierarchical presentations: (1) with cardiac arrest/ventricular arrhythmia; (2) with acute coronary syndrome; (3) with rapid atrial fibrillation; (4) with acute breathle...
This report describes prospective, cross‐sectional study conducted at Chiang Mai University. One hundred and fourteen patients were recruited in the study. All of the patients were diagnosed as having HFrEF, AF or both and had been receiving digoxin for at least 4 weeks. The SDC of each patient was measured at steady state and assigned to one of 3 groups according to the classifications of the Digitalis Investigation Group (DIG) trial: in the therapeutic range, over the therapeutic range and in the suboptimal range. Results and discussionThere were significant correlations between the measured and predicted SDCs usi...
ConclusionLevosimendan appears to be a promising drug to reduce mortality and worsening HF in patients with HF/CS-ACS. It appears to provide hemodynamic benefit and was associated with an increased risk of hypotension.
CONCLUSIONS: New onset SVA was prevalent in AA patients with severe sepsis and occurred more frequently with advanced age, increased severity of illness, congestive heart failure, and acute respiratory failure; it was associated with higher unadjusted in hospital mortality. However, after multiple adjustments, new onset SVA did not remain an independent predictor of mortality. PMID: 27103771 [PubMed - as supplied by publisher]
ConclusionAF is common in patients with HCM who need a CRM device. More than 50% of these patients develop de novo AF that was predominantly subclinical in our cohort.This article is protected by copyright. All rights reserved
Conclusion In the setting of elevated troponin, serious complications associated with either exercise or vasodilator stress testing appear to be relatively rare with no increased risk attributable to a particular vasodilator agent.